Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.76 |
| ▸ | HDAC3 | O15379 | 12/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.76 |
| ▸ | HDAC2 | Q92769 | 12/20 | 0.76 |
| ▸ | HDAC4 | P56524 | 10/20 | 0.76 |
| ▸ | HDAC7 | Q8WUI4 | 10/20 | 0.76 |
| ▸ | HDAC10 | Q969S8 | 10/20 | 0.76 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.76 |
| ▸ | HDAC8 | Q9BY41 | 10/20 | 0.76 |
| ▸ | HDAC9 | Q9UKV0 | 10/20 | 0.76 |
| ▸ | HDAC5 | Q9UQL6 | 10/20 | 0.76 |
| ▸ | LTA4H | P09960 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL675763 | 0.86 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL1232527 | 0.86 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL14861225 | 0.86 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL13039726 | 0.85 | HDAC6 (0.97) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL2227403 | 0.84 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL2226681 | 0.83 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL15800169 | 0.82 | HDAC6 (0.76) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL11052376 | 0.81 | ESRRG (0.70) | — | |
| SCHEMBL10086137 | 0.81 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC4 | |
| SCHEMBL2224905 | 0.81 | HDAC6 (1.00) | HDAC6HDAC3HDAC1HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | claimed |
| US-20220249477-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | claimed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20240390375-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | Viracta Subsidiary, Inc. (US) | 2024-11-28 | — | — | US | disclosed |
| US-20240342172-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | VIRACTA THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | US | disclosed |
| WO-2024192348-A2 | METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS | OHIO STATE INNOVATION FOUNDATION (US) | 2024-09-19 | — | — | WO | disclosed |
| US-12083119-B2 | Methods and compositions for treating viral or virally-induced conditions | Viracta Subsidiary, Inc. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240100079-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-28 | — | — | US | disclosed |
| US-20230346788-A1 | METHODS FOR TREATING VIRAL DISORDERS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-11-02 | — | — | US | disclosed |
| US-11701363-B2 | Methods for treating viral disorders | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| EP-4194548-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | Janssen Biotech, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-8993581-B2 | Methods for treating viral disorders | TRUSTEES OF BOSTON UNIVERSITY (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140045774-A1 | METHODS FOR TREATING VIRAL DISORDERS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130331313-A1 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | TRUSTEES OF BOSTON UNIVERSITY | 2013-12-12 | — | — | US | disclosed |
| WO-2012007725-A2 | METHOD OF REPROGRAMMING A CELL | PLASTICELL LTD (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20110245154-A1 | Methods and Compositions for Treating Viral or Virally-Induced Conditions | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| WO-2011113013-A2 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011060268-A2 | DIAGNOSIS AND TREATMENT OF CANCER USING HISTONE DEACETYLASE INHIBITORS AND RADIOLABELED METAIODOBENZYLGUANIDINE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110086869-A1 | METHODS FOR TREATING VIRAL DISORDERS | THE TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2011038224-A1 | METHODS FOR TREATING VIRAL DISORDERS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2011-03-31 | — | — | WO | disclosed |